A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection

计划入组 119 人 · 首次发布于 2020 年 11 月 20 日

Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults

计划入组 48 人 · 首次发布于 2012 年 4 月 5 日

Evaluating the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants

首次发布于 2019 年 8 月 1 日

GEO-CM02

GOVX-B11

GEO-ZM02

GEM PHARMACEUTICALS

India

GEON CORPORATION

Taiwan

MSA Safety

Egypt

GeoVax Receives EMA Approval to Skip Phase 1/2 Trials for Mpox Vaccine, Accelerating Path to Market

GeoVax Advances Multi-Antigen COVID-19 Vaccine and Expands Oncology Pipeline Despite BARDA Setback

GeoVax CEO David Dodd to Present at 2026 Georgia Life Sciences Summit as Company Advances MVA Vaccine and Oncology Pipeline